Castor’s addition of Virtual Visits to the company’s platform was conceptualized to reach trial participants in their own homes. The platform’s addition, however, further enables the decentralized clinical trial (DCT) solutions provider to allow researchers to further facilitate direct data collection in trials.
Derk Arts, CEO and Founder of Castor explained that Virtual Visits allow for researchers to conduct virtual visits through Castor’s electronic data collection (EDC) module to enable direct data capture during virtual visits.
According to Arts, Virtual Visits was created with the goal of making clinical trials easier for everyone involved. Stakeholders including researchers managing multiple studies or participants juggling daily life commitments.
Arts added that the addition to the DCT platform provides researchers with the ability “to ensure that patients can remotely connect with investigators or study coordinators on any device they want, in their preferred language – giving them the power to make informed decisions about their care.”
“Some patient engagement tools [used with the platform] could mean participants giving advice on trial designs or tracking their own data using wearable devices and mobile applications,” stated Arts.
The solution is compliant with HIPPA and GDPR regulations and provides patient privacy and data security.
Shortly after sharing the news of the launch of Virtual Visits, Castor announced its latest offering of pre-configured modules to increase recruitment, screening, enrollment, and engagement in clinical trials.
The latest offering, Castor Real World Evidence (RWE), integrates real-world data (RWD) sources like patient-reported outcomes with wearables. According to Castor CPTO Andy Sadler this new offering is “a natural extension” of the company’s platform.
Castor RWE includes pre-configured modules to help sponsors uncover trial insights into drug performance in real world settings while expanding trial access to global populations.
“RWE has the potential to transform evidence-based medicine, by generating a body of evidence that provides a much more accurate view on what cure is best for each individual patient, through including a diverse range of patients in everyday settings,” said Arts.
Castor stated it predicts its new offering can reduce trial cost by thirty percent and deployment timelines to only four weeks as the platform extends a trial’s global reach. This prediction stems from the platforms ability to accelerate the collection of RWD allowing companies to meet regulatory and payer requirements faster.